CreativeOne Wealth LLC Raises Position in Boston Scientific Corporation $BSX

CreativeOne Wealth LLC increased its holdings in Boston Scientific Corporation (NYSE:BSX) by 36.1% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 7,679 shares of the medical equipment provider’s stock after purchasing an additional 2,037 shares during the quarter. CreativeOne Wealth LLC’s holdings in Boston Scientific were worth $775,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its position in Boston Scientific by 1.3% in the 1st quarter. Vanguard Group Inc. now owns 134,588,729 shares of the medical equipment provider’s stock worth $13,577,311,000 after purchasing an additional 1,697,945 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main increased its position in shares of Boston Scientific by 2.5% in the fourth quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 22,312,967 shares of the medical equipment provider’s stock valued at $1,992,994,000 after acquiring an additional 554,388 shares during the period. Invesco Ltd. increased its position in shares of Boston Scientific by 5.3% in the first quarter. Invesco Ltd. now owns 16,624,940 shares of the medical equipment provider’s stock valued at $1,677,124,000 after acquiring an additional 834,274 shares during the period. Goldman Sachs Group Inc. increased its position in shares of Boston Scientific by 10.8% in the first quarter. Goldman Sachs Group Inc. now owns 14,143,332 shares of the medical equipment provider’s stock valued at $1,426,779,000 after acquiring an additional 1,383,524 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Boston Scientific by 18.7% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 10,839,362 shares of the medical equipment provider’s stock valued at $968,172,000 after acquiring an additional 1,709,461 shares during the period. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Insider Buying and Selling at Boston Scientific

In related news, EVP Arthur C. Butcher sold 17,313 shares of the business’s stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the sale, the executive vice president owned 23,600 shares of the company’s stock, valued at $2,469,268. The trade was a 42.32% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Michael F. Mahoney sold 164,443 shares of the business’s stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $103.69, for a total transaction of $17,051,094.67. Following the sale, the chief executive officer directly owned 1,476,882 shares in the company, valued at $153,137,894.58. The trade was a 10.02% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 345,029 shares of company stock valued at $35,976,603 over the last three months. 0.50% of the stock is currently owned by corporate insiders.

Boston Scientific Price Performance

Shares of NYSE BSX opened at $105.56 on Friday. Boston Scientific Corporation has a 1 year low of $79.53 and a 1 year high of $108.94. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82. The company’s 50-day moving average is $104.53 and its 200 day moving average is $102.15. The stock has a market capitalization of $156.41 billion, a P/E ratio of 62.83, a P/E/G ratio of 2.54 and a beta of 0.66.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.72 by $0.03. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The company had revenue of $5.06 billion for the quarter, compared to analysts’ expectations of $4.89 billion. During the same quarter in the previous year, the company earned $0.62 earnings per share. Boston Scientific’s quarterly revenue was up 22.8% on a year-over-year basis. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, sell-side analysts expect that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have issued reports on BSX shares. UBS Group boosted their price objective on shares of Boston Scientific from $130.00 to $135.00 and gave the company a “buy” rating in a research report on Thursday, July 24th. Jefferies Financial Group restated a “hold” rating on shares of Boston Scientific in a research report on Monday, July 21st. Leerink Partners started coverage on shares of Boston Scientific in a research report on Monday, June 16th. They issued an “outperform” rating and a $118.00 price objective on the stock. Leerink Partnrs upgraded shares of Boston Scientific to a “strong-buy” rating in a research report on Monday, June 16th. Finally, Needham & Company LLC restated a “buy” rating and issued a $115.00 price objective on shares of Boston Scientific in a research report on Wednesday, May 28th. Three research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, Boston Scientific currently has an average rating of “Buy” and a consensus price target of $117.50.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.